$TRVI
Trevi Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000156459022037385 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.340M $2.636M $2.229M
YoY Change 11.75% 18.26% -7.89%
% of Gross Profit
Research & Development $4.317M $5.769M $4.718M
YoY Change -30.13% 22.28% -2.28%
% of Gross Profit
Depreciation & Amortization $15.00K $9.000K $13.00K
YoY Change 25.0% -30.77% 30.0%
% of Gross Profit
Operating Expenses $6.657M $8.405M $6.947M
YoY Change -19.53% 20.99% -4.1%
Operating Profit -$8.405M -$6.947M
YoY Change 20.99% -4.1%
Interest Expense $843.0K $292.0K $303.0K
YoY Change -433.2% -3.63% 104.73%
% of Operating Profit
Other Income/Expense, Net $289.0K $132.0K $0.00
YoY Change -100.0%
Pretax Income -$5.525M -$8.273M -$7.253M
YoY Change -35.2% 14.06% -1.84%
Income Tax -$20.00K -$7.000K $2.000K
% Of Pretax Income
Net Earnings -$5.505M -$8.266M -$7.255M
YoY Change -35.39% 13.94% -1.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.34
Diluted Earnings Per Share -$0.09 -$0.12 -$335.8K
COMMON SHARES
Basic Shares Outstanding 59.92M 42.77M 21.61M
Diluted Shares Outstanding 68.90M 21.61M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $120.5M $125.6M $29.32M
YoY Change 227.21% 328.42% -44.98%
Cash & Equivalents $12.59M $66.57M $29.30M
Short-Term Investments $107.9M $59.03M
Other Short-Term Assets $1.311M $421.0K $1.389M
YoY Change 443.98% -69.69% -25.32%
Inventory
Prepaid Expenses $795.0K $1.294M
Receivables
Other Receivables
Total Short-Term Assets $122.6M $127.3M $30.71M
YoY Change 223.04% 314.62% -44.38%
LONG-TERM ASSETS
Property, Plant & Equipment $170.0K $68.00K $222.0K
YoY Change 220.75% -69.37% -38.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $205.0K $922.0K $667.0K
YoY Change -38.62% 38.23% 115.16%
Total Long-Term Assets $399.0K $1.043M $889.0K
YoY Change -22.97% 17.32% 32.69%
TOTAL ASSETS
Total Short-Term Assets $122.6M $127.3M $30.71M
Total Long-Term Assets $399.0K $1.043M $889.0K
Total Assets $123.0M $128.4M $31.60M
YoY Change 219.73% 306.26% -43.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.857M $2.333M $2.233M
YoY Change 0.28% 4.48% 77.22%
Accrued Expenses $3.518M $5.249M $3.360M
YoY Change -7.62% 56.22% -28.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.000M $7.000M $4.250M
YoY Change 17.71% 64.71%
Total Short-Term Liabilities $13.40M $14.64M $9.913M
YoY Change 5.31% 47.69% 62.51%
LONG-TERM LIABILITIES
Long-Term Debt $2.151M $3.800M $10.25M
YoY Change -75.14% -62.91% -26.77%
Other Long-Term Liabilities $3.000K $15.00K $58.00K
YoY Change -87.5% -74.14% -65.88%
Total Long-Term Liabilities $3.000K $15.00K $10.30M
YoY Change -99.97% -99.85% -27.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.40M $14.64M $9.913M
Total Long-Term Liabilities $3.000K $15.00K $10.30M
Total Liabilities $15.56M $18.46M $20.22M
YoY Change -27.31% -8.7% -0.22%
SHAREHOLDERS EQUITY
Retained Earnings -$210.1M -$204.6M -$172.4M
YoY Change 16.13% 18.66% 25.42%
Common Stock $60.00K $58.00K
YoY Change 106.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $107.5M $109.9M $11.38M
YoY Change
Total Liabilities & Shareholders Equity $123.0M $128.4M $31.60M
YoY Change 219.73% 306.26% -43.46%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$5.505M -$8.266M -$7.255M
YoY Change -35.39% 13.94% -1.67%
Depreciation, Depletion And Amortization $15.00K $9.000K $13.00K
YoY Change 25.0% -30.77% 30.0%
Cash From Operating Activities -$6.331M -$8.576M -$7.241M
YoY Change 1.64% 18.44% 3.89%
INVESTING ACTIVITIES
Capital Expenditures $116.0K -$43.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$48.19M -$4.807M
YoY Change
Cash From Investing Activities -$48.31M -$4.850M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 652.0K 55.30M 134.0K
YoY Change -95.26% 41170.15% -99.17%
NET CHANGE
Cash From Operating Activities -6.331M -8.576M -7.241M
Cash From Investing Activities -48.31M -4.850M 0.000
Cash From Financing Activities 652.0K 55.30M 134.0K
Net Change In Cash -53.99M 41.88M -7.107M
YoY Change -818.65% -689.22% -178.1%
FREE CASH FLOW
Cash From Operating Activities -$6.331M -$8.576M -$7.241M
Capital Expenditures $116.0K -$43.00K $0.00
Free Cash Flow -$6.447M -$8.533M -$7.241M
YoY Change 3.5% 17.84% 4.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
886000
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
120000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24000
dei Document Type
DocumentType
10-Q
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59922945
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66574000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1294000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
421000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
922000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53000
CY2021Q4 us-gaap Assets
Assets
38475000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2849000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3808000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2333000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
424000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5249000
CY2022Q3 us-gaap Loans Payable Current
LoansPayableCurrent
7000000
CY2021Q4 trvi Derivative Fair Value Of Derivative Liability Current
DerivativeFairValueOfDerivativeLiabilityCurrent
114000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0834299
dei Entity Address Address Line1
EntityAddressAddressLine1
195 Church Street
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
TRVI
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14641000
CY2022Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
3800000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
8652000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38886
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
304-2499
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53221949
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20390852
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2022Q3 us-gaap Assets Current
AssetsCurrent
127318000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
37957000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
59029000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
131000
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
5833000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12724000
CY2021Q4 us-gaap Liabilities
Liabilities
21400000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28505804
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28505804
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
197963000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180917000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6947000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23250000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
29000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1232000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25435000
us-gaap Net Income Loss
NetIncomeLoss
-25420000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20390852
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20390852
us-gaap Net Income Loss
NetIncomeLoss
-25420000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25420000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29318000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06510
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001563880
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Registrant Name
EntityRegistrantName
TREVI THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36830000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
241000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
334000
CY2022Q3 us-gaap Assets
Assets
128361000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2000
trvi Stock Issued During Period Value Stock Warrant Exercised
StockIssuedDuringPeriodValueStockWarrantExercised
11782000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
263000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
132000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-306000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
623000
CY2022Q3 us-gaap Interest Expense
InterestExpense
292000
CY2021Q3 us-gaap Interest Expense
InterestExpense
303000
us-gaap Interest Expense
InterestExpense
889000
us-gaap Interest Expense
InterestExpense
893000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
15000
CY2022Q3 us-gaap Liabilities
Liabilities
18458000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58322517
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58322517
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
58000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
314672000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-263000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204564000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
109903000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
17075000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128361000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38475000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5769000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4718000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15517000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16805000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2636000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2229000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7733000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7398000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8405000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6947000
us-gaap Operating Expenses
OperatingExpenses
23250000
us-gaap Operating Expenses
OperatingExpenses
24203000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8405000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24203000
CY2021Q3 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-5000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-147000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
375000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-413000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8273000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7253000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23663000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-15000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8266000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7255000
us-gaap Net Income Loss
NetIncomeLoss
-23647000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-128000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-263000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8394000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7255000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23910000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60515000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
569000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
CY2022Q3 trvi Stock Issued During Period Value Stock Warrant Exercised
StockIssuedDuringPeriodValueStockWarrantExercised
5890000
CY2022Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
128000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
68898810
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68898810
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
21607979
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21607979
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
53221949
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53221949
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8266000
trvi Proceeds From At Market Sales Net Of Commissions
ProceedsFromAtMarketSalesNetOfCommissions
7505000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
195000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
420000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8266000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
110655000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
109903000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
17736000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7255000
us-gaap Net Income Loss
NetIncomeLoss
-23647000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
540000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7255000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7034000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
11380000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
17075000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1826000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59067000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
23000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4083000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
21000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
68000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
103010000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11782000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
139000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
23000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
17000
us-gaap Net Income Loss
NetIncomeLoss
-23647000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
109903000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27282000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2003000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
17000
us-gaap Net Income Loss
NetIncomeLoss
-25420000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
11380000
us-gaap Net Income Loss
NetIncomeLoss
-23647000
us-gaap Net Income Loss
NetIncomeLoss
-25420000
us-gaap Depreciation
Depreciation
28000
us-gaap Depreciation
Depreciation
38000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
268000
trvi Changes In Fair Value Of Term Loan Derivative Liability
ChangesInFairValueOfTermLoanDerivativeLiability
147000
trvi Changes In Fair Value Of Term Loan Derivative Liability
ChangesInFairValueOfTermLoanDerivativeLiability
-29000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
419000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
442000
trvi Expense Related To Other Transactions
ExpenseRelatedToOtherTransactions
375000
us-gaap Share Based Compensation
ShareBasedCompensation
1826000
us-gaap Share Based Compensation
ShareBasedCompensation
2003000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
492000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
122000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-527000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
216000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
670000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-220000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21844000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22717000
trvi Proceeds From Maturities Of Available For Sale Marketable Securities
ProceedsFromMaturitiesOfAvailableForSaleMarketableSecurities
2001000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
61025000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29744000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15683000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36830000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45001000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66574000
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Nature of the Business </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trevi Therapeutics, Inc. (“Trevi” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (“IPF”) and other chronic cough indications, and for the treatment of prurigo nodularis. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Due to nalbuphine’s mechanism of action as a modulator of opioid receptors, the Company believes Haduvio has the potential to be effective in treating each of these conditions. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Haduvio is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed κ-opioid receptor agonist and μ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States (“U.S.”) and Europe. The κ- and μ-opioid receptors are known to be critical mediators of cough, itch and certain movement disorders. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with μ-opioid agonists because it antagonizes or blocks, the μ-opioid receptor. Parenteral nalbuphine is not scheduled as a controlled substance in the U.S. and most of Europe.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these Condensed Consolidated Financial Statements include, but are not limited to, the recognition of research and development (“R&amp;D”) expenses, the valuation of stock-based awards and the valuation allowance of deferred tax assets resulting from net operating losses. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p>
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022Q3 trvi Other Than Temporary Impairment Losses Marketable Securities
OtherThanTemporaryImpairmentLossesMarketableSecurities
0
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
trvi Other Than Temporary Impairment Losses Marketable Securities
OtherThanTemporaryImpairmentLossesMarketableSecurities
0
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59292000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
263000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59029000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.130
trvi Number Of New Leases
NumberOfNewLeases
0
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
131000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
120000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
61000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
144000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
36000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
25000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
64000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
61000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
36000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
35000
us-gaap Operating Lease Payments
OperatingLeasePayments
95000
us-gaap Operating Lease Payments
OperatingLeasePayments
104000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5249000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3808000
CY2022Q3 trvi Accrued Research And Development Liabilities
AccruedResearchAndDevelopmentLiabilities
3018000
CY2021Q4 trvi Accrued Research And Development Liabilities
AccruedResearchAndDevelopmentLiabilities
2303000
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1069000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1250000
CY2022Q3 trvi Accrued Consulting And Professional Fees
AccruedConsultingAndProfessionalFees
747000
CY2021Q4 trvi Accrued Consulting And Professional Fees
AccruedConsultingAndProfessionalFees
176000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
415000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
79000
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
84207857
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
55139084
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2929472
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1352250
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
52513
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
36297
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
51005
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.73
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4141907
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.35
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2107177
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.68
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2034730
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.99
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
569000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
540000
us-gaap Share Based Compensation
ShareBasedCompensation
1826000
us-gaap Share Based Compensation
ShareBasedCompensation
2003000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8266000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7255000
us-gaap Net Income Loss
NetIncomeLoss
-23647000
us-gaap Net Income Loss
NetIncomeLoss
-25420000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68898810
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68898810
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21607979
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21607979
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53221949
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20390852
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13845611
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3049180

Files In Submission

Name View Source Status
0001564590-22-037385-index-headers.html Edgar Link pending
0001564590-22-037385-index.html Edgar Link pending
0001564590-22-037385.txt Edgar Link pending
0001564590-22-037385-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trvi-10q_20220930.htm Edgar Link pending
trvi-20220930.xsd Edgar Link pending
trvi-ex101_115.htm Edgar Link pending
trvi-ex311_8.htm Edgar Link pending
trvi-ex312_9.htm Edgar Link pending
trvi-ex321_7.htm Edgar Link pending
trvi-ex322_6.htm Edgar Link pending
trvi-20220930_def.xml Edgar Link unprocessable
trvi-20220930_lab.xml Edgar Link unprocessable
trvi-20220930_pre.xml Edgar Link unprocessable
trvi-10q_20220930_htm.xml Edgar Link completed
trvi-20220930_cal.xml Edgar Link unprocessable